Cartesian Therapeutics, Inc. — Director's Dealing 2016

Jun 22, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2016-06-21

Reporting Person: Flagship Ventures Fund 2007, L.P. (Director, 10% Owner)
Reporting Person: Flagship Ventures 2007 General Partner LLC (Director, 10% Owner)
Reporting Person: AFEYAN NOUBAR (Director, 10% Owner)
Reporting Person: KANIA EDWIN M JR (Director, 10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	31115	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock	$		Common Stock (318752)		Indirect
Series B Convertible Preferred Stock	$		Common Stock (631458)		Indirect
Series C Convertible Preferred Stock	$		Common Stock (235042)		Indirect
Series D Convertible Preferred Stock	$		Common Stock (241718)		Indirect
Series E Convertible Preferred Stock	$		Common Stock (125008)		Indirect
Common Warrants	$17.55	2018-07-24	Common Stock (20262)		Indirect

Footnotes

F1: Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.

F2: The preferred stock is convertible at any time, at the holder's election and has no expiration date. The preferred stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.